Dr. Lal Path Labs Limited has released the transcript of its Q3 and 9M FY26 earnings conference call, which took place on January 30, 2026. The call, lasting approximately one hour, featured management speakers including Executive Chairman (Hony) Brig. Dr. Arvind Lal, CEO Mr. Shankha Banerjee, and Group CFO and CEO International Business Mr. Ved Prakash Goel. The transcript details discussions on the company's strategic priorities, including the launch of its personalized preventive healthcare platform, Sovaaka, expansion of specialized testing capabilities, and deepening presence in underpenetrated markets. Key performance highlights for Q3 FY26 included a 10.6% YoY revenue growth to ₹660 crore, with 9-month revenue reaching ₹2,060 crore. Patient volume growth was 2.7% in Q3, impacted by a decline in the seasonal fever portfolio. EBITDA before exceptional items grew by 16.3% to ₹179 crore in Q3, with a margin of 27.2%. Profit after tax for Q3 FY26 was ₹91 crore. The company also announced an interim dividend of 35% (₹3.5 per share). Discussions also covered the performance of Swasthfit, expansion into Tier 2 and Tier 3 towns, and the company's strategy for advanced radiology and the Sovaaka initiative. Management addressed questions regarding revenue growth drivers, margin sustainability, CAPEX plans, and potential inorganic growth opportunities. The company reiterated its focus on organic growth and disciplined financial prudence.
